According to a recently-filed 13D, notorious investor Seth Klarman‘s Baupost Group currently owns a substantial position in the OTC stock Biotie Therapies Corp (OTCMKTS:BIOZF). The filing showed that Baupost owns 172.71 million shares of Biotie Therapies Corp, the activist position amassing over 17% of the company’s outstanding stock.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| The Baupost Group, L.L.C.04-3402144 | 0 | 172,711,112 | 0 | 172,711,112 | 172,711,112 | 17.1% |
| SAK Corporation04-3334541 | 0 | 172,711,112 | 0 | 172,711,112 | 172,711,112 | 17.1% |
| Seth A. Klarman | 0 | 172,711,112 | 0 | 172,711,112 | 172,711,112 | 17.1% |
Follow Seth Klarman's Baupost Group
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 6 SEC Filing
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13D
Under
the Securities Exchange Act of 1934
(Amendment
No.
n/a
)*
Biotie Therapies Corp.
(Name of
Issuer)
Common Stock
(Title of
Class of Securities)
09074D103
(CUSIP
Number)
Seth A. Klarman,
The Baupost Group, L.L.C.
10 St. James Avenue, Suite 1700,
The Baupost Group, L.L.C.
10 St. James Avenue, Suite 1700,
Boston,
Massachusetts
02116
Phone : (617) 210-8300
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
January 19, 2016
(Date of
Event which Requires Filing of this Statement)
If the
filing person has previously filed a statement on Schedule 13G to report the
acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box.
x
Note: Schedules filed in paper
format shall include a signed original and five copies of the schedule,
including all exhibits. See §240.13d-7 for other parties to whom copies are to
be sent.
format shall include a signed original and five copies of the schedule,
including all exhibits. See §240.13d-7 for other parties to whom copies are to
be sent.
* The
remainder of this cover page shall be filled out for a reporting person’s
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The
information required on the remainder of this cover page shall not be deemed to
be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 6
